摘要
目的评价低剂量（1mg）曲安奈德玻璃体内注射治疗视网膜中央静脉阻塞继发囊样黄斑水肿的疗效及安全性。方法回顾性分析60例60眼视网膜中央静脉阻塞继发黄斑水肿的临床资料。随机分为3组，1mg组（玻璃体内注射曲安奈德1mg）、4mg组（注药4mg）及对照组（未注药），每组20例20只眼。比较3组患者注药前及注药后1周、1月和3月的最佳矫正视力（BCVA）及黄斑中心凹厚度（CMT），并对术后并发症如高眼压，晶体浑浊是否加重，是否发生眼内炎等进行观察。结果1mg组、4mg组及对照组的CMT在注药前的基线值依次为（493±123）μm、（479±116）μm和（486±131）μm，治疗后3个月时则依次为（243±86）μm、（256±78）μm和（380±103）μm，两注药组较对照组明显下降（P〈0．05）；而两种剂量组间的CMT差异无统计学意义（P〉0．05）。BCVA结果显示，注药后1个月，1mg组及4mg组与注药前相比视力明显提高（P〈0．05）。1mg组无一例发生术后并发症，如眼压升高、白内障加重及眼内炎等。4mg组有3例眼压升高，2例白内障加重。结论1mg及4mg两种剂量曲安奈德玻璃体内注射均可有效控制视网膜中央静脉阻塞继发的囊样黄斑水肿，但低剂量1mg曲安奈德玻璃体内注射更加安全，术后并发症发生率更低。
Objective To evaluate the effects and safety of intravitreal injection of a low dose （1 mg） triamicinolone acetonide （TA） for macular edema secondary to central retinal vein occlusion （CRVO）. Methods The data of 60 eyes of 60 patients with macular edema secondary to CRVO were retrospectively analysed. The patients were divided into three groups with 20 patients in each group, and patients in three groups received intravitreal injection of TA of 1 mg, 4 mg, and zero mg, respectively. Data on central macula thickness （ CMT）, best corrected visual acuity （ BCVA）, and complications at 1 week, 1 and 3 month after the injection were compared. Results All patients were followed up for 3 months. CMT decreased significantly from baseline at 1 week, 1 month and 3 months after the injection in TA treated groups compared with no TA group （P 〈0.05）. The baseline CMT values were （493±123）μm, （479±116）μm, and （486±131 ）μm （P 〉 0.05 ） in 1 mg TA, 4 mg TA and no TA control groups, respectively. While the CMT values were （243±86）μm, （256±78）μm, and （380±103）μm, respectively at 3 months time point. No significant differences were found between 1 mg TA group and 4 mg TA group at 1 month and 3 months time points （P 〉 0.05 ）. BCVA improved significantly from baseline at 1 month after intravitreal injection in two TA groups （P 〈 0.05 ）. No patients experienced complications such as ocular hypertension, cataract development, and infectious endophthalmitis in the 1 mg TA group. But three patients developed ocular hypertention and two patients experienced cataract development in 4mg TA group. Conclusion Both 1 mg and 4 mg dosages of TA are effective in treatment of macular edema secondary to CRVO. However, the 1 mg TA intravitreal injection leads to fewer complications.
出处
《中华眼外伤职业眼病杂志》
2015年第11期833-837,共5页
Chinese Journal of Ocular Trauma and Occupational Eye Disease
关键词
黄斑水肿
视网膜中央静脉阻塞
玻璃体内注射
曲安奈德
低剂量
1
mg
Macular edema
Central retinal vein occlusion
Intravitreal injection
Triamicinoloneacetonide, low dosage, 1 mg
